Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience

被引:4
|
作者
Foubert, Fanny [1 ]
Salimon, Maeva [1 ]
Dumars, Clotilde [2 ]
Regenet, Nicolas [3 ]
Girot, Paul [1 ]
Venara, Aurelien [4 ,5 ]
Senellart, Helene [6 ]
Heymann, Marie-Francoise [7 ]
Matysiak-Budnik, Tamara [1 ,5 ]
Touchefeu, Yann [1 ,5 ]
机构
[1] Nantes Univ Hosp, Dept Gastroenterol & Digest Oncol, IMAD, Nantes, France
[2] Nantes Univ Hosp, Dept Pathol, Nantes, France
[3] Nantes Univ Hosp, Dept Digest Surg, IMAD, Nantes, France
[4] Angers Univ Hosp, Dept Digest Surg, Angers, France
[5] Nantes Univ, INSERM, U1235, Nantes, France
[6] Canc Res Inst, Dept Med Oncol, St Herblain, France
[7] Canc Res Inst, Dept Pathol, St Herblain, France
关键词
Neuroendocrine tumors (NETs); pancreatic neuroendocrine tumors; intestinal neuroendocrine tumors; prognostic factors; survival; ENETS CONSENSUS GUIDELINES; METASTASES; MANAGEMENT; NEOPLASMS; EPIDEMIOLOGY; STANDARDS; RESECTION; DISEASE; CARE;
D O I
10.21037/jgo.2018.09.13
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Intestinal and pancreatic neuroendocrine tumors (IP-NETs) are rare tumors with heterogeneous outcomes. The aim of our study was to determine the clinical, therapeutic and pathological factors which impact the overall survival (OS) in IP-NETs. Methods: All the patients diagnosed with IP-NETs at the Nantes University Hospital between October 1994 and October 2013 were retrospectively analysed. Patients with MEN-1 (Type 1 Multiple Endocrine Neoplasia) or Von Hippel-Lindau syndrome were excluded. Additionally, a prospective analysis of tumor grade (mitotic index and Ki67 index) was performed on tumor samples. OS was evaluated by Kaplan-Meier method and prognostic factors by log-rank test and Cox model. Results: The study included 151 patients. Median age was 60 (range, 14-81). Primary tumor was pancreatic in 86 patients (56.95%) and intestinal in 65 patients (43.05%). Tumors were metastatic (synchronous or metachronous) in 72 patients (47.7%). The median OS was 157 months. For all IP-NETs, age >65 years (P<0.0001), Ki67 >5% (P=0.03), synchronous metastases (P=0.016), primary tumor size >25 mm (P=0.03) and emergency surgery (P=0.007) were independent poor prognostic factors. Conclusions: In this large series of patients with IP-NET, age >65 years, Ki67 >5%, primary tumor size >25 mm, synchronous metastases and emergency surgery for acute complications have been identified as independent poor prognostic factors.
引用
收藏
页码:103 / 111
页数:9
相关论文
共 50 条
  • [21] Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience
    Wong, Joyce
    Fulp, William J.
    Strosberg, Jonathan R.
    Kvols, Larry K.
    Centeno, Barbara A.
    Hodul, Pamela J.
    AMERICAN JOURNAL OF SURGERY, 2014, 208 (05): : 775 - 780
  • [22] Multidisciplinary Treatment Strategy for Advanced Pancreatic Neuroendocrine Tumors - A Single Center Experience
    Tsuchikawa, Takahiro
    Hirano, Satoshi
    Tanaka, Eiichi
    Kato, Kentaro
    Matsumoto, Joe
    Sichinohe, Toshiaki
    HEPATO-GASTROENTEROLOGY, 2012, 59 (120) : 2623 - 2626
  • [23] Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: A 12-year experience from a single center
    Zhou, Bo
    Duan, Jixuan
    Yan, Sheng
    Zhou, Jie
    Zheng, Shusen
    ONCOLOGY LETTERS, 2017, 13 (03) : 1157 - 1164
  • [24] EXPRESSION OF GROWTH-FACTORS AND THEIR RECEPTORS IN NEUROENDOCRINE GUT AND PANCREATIC TUMORS, AND PROGNOSTIC FACTORS FOR SURVIVAL
    OBERG, K
    MOLECULAR AND CELL BIOLOGICAL ASPECTS OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE, 1994, 733 : 46 - 55
  • [25] Prognostic Factors and Survival in Nasopharyngeal Cancer: A Single Center Experience
    Balsak, Atalay
    Cobanoglu, Bengu
    Kandaz, Mustafa
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2024, 34 (01): : 35 - 44
  • [26] Survival and prognostic factors in cholangiocarcinoma: A single-center experience
    Payapwattanawong, S.
    Maneenil, K.
    Limtapatip, S.
    Laohavinij, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] RECURRENCE AND SURVIVAL OF LOCALIZED NEUROENDOCRINE TUMORS OF THE RECTUM: SINGLE CENTER EXPERIENCE.
    Storino, A.
    Wong, D.
    Ore, A.
    Fuentes, I. A. Gaytan
    Fabrizio, A.
    Cataldo, T. E.
    Messaris, E.
    DISEASES OF THE COLON & RECTUM, 2020, 63 (06) : E192 - E193
  • [28] Pancreatic Neuroendocrine Tumors: Experience of a Tertiary Care Center
    Assi, R.
    Hakim, A.
    Mukherji, D.
    Abdel-Massih, S.
    Charafeddine, M.
    Temraz, S.
    Shamseddine, A.
    NEUROENDOCRINOLOGY, 2016, 103 : 28 - 28
  • [29] Pancreatic Neuroendocrine Tumors: Experience in a Spanish Reference Center
    Tejera, C.
    Flores, J. A.
    Barzola Navarro, E. J.
    Rubio, A.
    Galeano, F.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 233 - 234
  • [30] GASTRIC NEUROENDOCRINE TUMORS: A SINGLE CENTER EXPERIENCE
    Ioannis, Pilpilidis
    Dimitrios, Tzilves
    Kostas, Soufleris
    Georgia, Lazaraki
    Persefoni, Xiroy
    Kostas, Skordas
    Anestis, Tarpagos
    ANNALS OF ONCOLOGY, 2014, 25